-
Phase 3
-
-
18+Age Range
-
241Locations
-
Recruiting
Recruiting
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Active Comparator: Daratumumab in combination with dexamethasone and bortezomib
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 1
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 2
Experimental: Daratumumab in combination with Iberdomide and dexamethasone - Dose 3